What is the current valuation of the France Radioligand Therapy Rlt Market?

The market valuation was 0.326 USD Billion in 2024. Read More

What is the projected market size for the France Radioligand Therapy Rlt Market by 2035?

The projected valuation for 2035 is 0.8 USD Billion. Read More

What is the expected CAGR for the France Radioligand Therapy Rlt Market during the forecast period?

The expected CAGR from 2025 to 2035 is 8.52%. Read More

How is the France Radioligand Therapy Rlt Market segmented by application?

The market segments by application include Oncology, Cardiology, Neurology, and Endocrinology. Read More

What were the valuations for the Oncology segment in 2024?

The Oncology segment was valued at 0.15 USD Billion in 2024 and is projected to reach 0.4 USD Billion. Read More

What is the market segmentation by end use in the France Radioligand Therapy Rlt Market?

The market segments by end use include Hospitals, Diagnostic Centers, Research Institutions, and Pharmaceutical Companies. Read More

What were the projected valuations for the Hospitals segment in 2024?

The Hospitals segment was valued at 0.13 USD Billion in 2024 and is expected to grow to 0.32 USD Billion. Read More

How is the market segmented by the type of radioligand?

The market segments by type of radioligand include Alpha Emitters, Beta Emitters, Auger Electron Emitters, and Radionuclide Therapy. Read More

What are the target diseases in the France Radioligand Therapy Rlt Market?

Target diseases include Prostate Cancer, Neuroendocrine Tumors, Lung Cancer, and Thyroid Cancer. Read More

France Radioligand Therapy Market

Q: Which companies are the key players in the France Radioligand Therapy Rlt Market?

Key players include Novartis, Bayer, Elekta, Lantheus, Ipsen, Advanced Accelerator Applications, TheraP, and Point Biopharma. Read More

ID: MRFR/Pharma/50333-HCR

200 Pages

Rahul Gotadki

Last Updated: March 28, 2026

France Radioligand Therapy RLT Market Research Report: Size, Share, Trend Analysis By Isotope (Fluorine – 18, Gallium – 68, Lutetium – 177, Others), By Targeted Receptor (Prostate-specific Membrane Antigen (PSMA), Somatostatin Receptor (SSTR), Epidermal Growth Factor Receptor (EGFR), Others), By Indication (Prostate Cancer, Neuroendocrine Tumors (NETs), Breast Cancer, Others) and By End Users (Hospitals & Clinics, Diagnostic Centers, Others) - Growth Outlook & Industry Forecast 2025 To 2035

France Radioligand Therapy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.52%

2024 Market Size$ 0.33 Billion

2025 Market Size$ 0.36 Billion

2035 Market Size$ 0.8 Billion

Key Players

Novartis

Bayer

Elekta

Lantheus

Ipsen

Advanced Accelerator Applications

Trends

Emergence of Targeted Therapies
Regulatory Support and Innovation
Collaboration in Research and Development

Opportunities

Growing Incidence of Cancer
Supportive Regulatory Framework
Advancements in Nuclear Medicine

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Healthcare, BY Application (USD Billion)
  1. 4.1.1 Oncology
  2. 4.1.2 Cardiology
  3. 4.1.3 Neurology
  4. 4.1.4 Endocrinology
2. 4.2 Healthcare, BY End Use (USD Billion)
  1. 4.2.1 Hospitals
  2. 4.2.2 Diagnostic Centers
  3. 4.2.3 Research Institutions
  4. 4.2.4 Pharmaceutical Companies
3. 4.3 Healthcare, BY Type of Radioligand (USD Billion)
  1. 4.3.1 Alpha Emitters
  2. 4.3.2 Beta Emitters
  3. 4.3.3 Auger Electron Emitters
  4. 4.3.4 Radionuclide Therapy
4. 4.4 Healthcare, BY Administration Route (USD Billion)
  1. 4.4.1 Intravenous
  2. 4.4.2 Oral
  3. 4.4.3 Intratumoral
5. 4.5 Healthcare, BY Target Disease (USD Billion)
  1. 4.5.1 Prostate Cancer
  2. 4.5.2 Neuroendocrine Tumors
  3. 4.5.3 Lung Cancer
  4. 4.5.4 Thyroid Cancer
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Healthcare
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Novartis (FR)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bayer (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Elekta (FR)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Lantheus (FR)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Ipsen (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Advanced Accelerator Applications (FR)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 TheraP (FR)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Point Biopharma (FR)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 FRANCE MARKET ANALYSIS BY APPLICATION
3. 6.3 FRANCE MARKET ANALYSIS BY END USE
4. 6.4 FRANCE MARKET ANALYSIS BY TYPE OF RADIOLIGAND
5. 6.5 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE
6. 6.6 FRANCE MARKET ANALYSIS BY TARGET DISEASE
7. 6.7 KEY BUYING CRITERIA OF HEALTHCARE
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF HEALTHCARE
10. 6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
11. 6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
12. 6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
13. 6.13 HEALTHCARE, BY APPLICATION, 2024 (% SHARE)
14. 6.14 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion)
15. 6.15 HEALTHCARE, BY END USE, 2024 (% SHARE)
16. 6.16 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion)
17. 6.17 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 (% SHARE)
18. 6.18 HEALTHCARE, BY TYPE OF RADIOLIGAND, 2024 TO 2035 (USD Billion)
19. 6.19 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE)
20. 6.20 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion)
21. 6.21 HEALTHCARE, BY TARGET DISEASE, 2024 (% SHARE)
22. 6.22 HEALTHCARE, BY TARGET DISEASE, 2024 TO 2035 (USD Billion)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 France MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY APPLICATION, 2026-2035 (USD Billion)
  2. 7.2.2 BY END USE, 2026-2035 (USD Billion)
  3. 7.2.3 BY TYPE OF RADIOLIGAND, 2026-2035 (USD Billion)
  4. 7.2.4 BY ADMINISTRATION ROUTE, 2026-2035 (USD Billion)
  5. 7.2.5 BY TARGET DISEASE, 2026-2035 (USD Billion)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

France Radioligand Therapy Market Segmentation

France Radioligand Therapy Market By Application (USD Billion, 2026-2035)

Oncology
Cardiology
Neurology
Endocrinology

France Radioligand Therapy Market By End Use (USD Billion, 2026-2035)

Hospitals
Diagnostic Centers
Research Institutions
France Radioligand Therapy Market Companies

France Radioligand Therapy Market By Type of Radioligand (USD Billion, 2026-2035)

Alpha Emitters
Beta Emitters
Auger Electron Emitters
Radionuclide Therapy

France Radioligand Therapy Market By Administration Route (USD Billion, 2026-2035)

Intravenous
Oral
Intratumoral

France Radioligand Therapy Market By Target Disease (USD Billion, 2026-2035)

Prostate Cancer
Neuroendocrine Tumors
Lung Cancer
Thyroid Cancer

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”